Selective Androgen Receptor Degraders May Become New Treatment for Castration Resistant Prostate Cancer

//Selective Androgen Receptor Degraders May Become New Treatment for Castration Resistant Prostate Cancer

New molecules called selective androgen receptor degraders (SARDs) might be helpful in fighting advanced prostate cancer, according to an industry-sponsored study presented April 1, at the 99th annual meeting of the Endocrine Society.

“If successful in the clinic, the novel highly potent SARDs discovered in this program could be used to treat many of the most aggressive and currently untreatable forms of prostate cancer,” said principal investigator Ramesh Narayanan, Ph.D., associate professor and director of the Center for Cancer Drug Discovery at the University of Tennessee Health Science Center in Memphis, Tenn.

“The clinical success of new AR-targeted therapies in patients with castration-resistant prostate cancer emphasizes the continued importance of the AR signaling axis in the disease,” he said. Narayanan created a series of SARDs that degrade all forms of the androgen receptor (AR) and may lead to new treatments for castration-resistant prostate cancer.

The unique pharmacology of the SARDs lets them bind, antagonize and degrade the AR along with mutants and splice variants (AR-SVs) and inhibit the growth of aggressive prostate cancers that are unresponsive to other androgen pathway inhibitors.

“In most cases, the AR promotes the growth of prostate cancer, and currently available AR antagonists do not provide sustained treatment. After a brief period of treatment, the cancer often relapses due to alterations (mutations or splices) in the AR. The altered AR promotes the robust growth of the cancer,” Narayanan said.

By contrast, “the molecules our group has discovered not only inhibit the AR, but they also degrade the AR and hence may have the potential to provide a more sustained treatment option than a conventional antagonist,” he added.

“Unlike other hormone receptors, the AR is difficult to degrade,” Narayanan explained. “The SARDs we have developed degrade the AR at pharmacologically achievable concentrations. Moreover, the molecules degrade spliced forms of the AR that do not contain a binding pocket, which was a surprise to the investigators.”

“Clinical development of these compounds will be initiated later this year,” he added.

By | 2017-10-19T10:45:50+00:00 April 7th, 2017|Advanced Prostate Cancer|0 Comments

About the Author:

Malecare is the world’s leading men’s cancer support and advocacy nonprofit organization.

Leave A Comment